# Artivion Announces Treatment of First Patient with Arcevo LSA in ARTIZEN Pivotal Trial
Canonical URL: https://biopharmsignal.com/news/AORT/artivion-announces-treatment-of-first-patient-with-arcevo-lsa-in-artizen-pivotal-trial
Ticker: AORT
Company: Artivion
Source: Artivion
Published: 2025-11-06 13:00 EST
Original Source URL: https://investors.artivion.com
## Summary

ATLANTA , Nov. 6, 2025 /PRNewswire/ --  Artivion, Inc. (NYSE: AORT),  a leading cardiac and vascular surgery company focused on aortic disease, today announced the treatment of the first patient in the ARTIZEN pivotal trial, evaluating the safety and effectiveness of the Arcevo™ LSA Hybrid Stent

## Article Body
ATLANTA , Nov. 6, 2025 /PRNewswire/ --  Artivion, Inc. (NYSE: AORT),  a leading cardiac and vascular surgery company focused on aortic disease, today announced the treatment of the first patient in the ARTIZEN pivotal trial, evaluating the safety and effectiveness of the Arcevo™ LSA Hybrid Stent
## Recent Company News
- 2026-05-18 11:00 EST — [Artivion Completes Acquisition of Endospan Ltd.](https://biopharmsignal.com/news/AORT/artivion-completes-acquisition-of-endospan-ltd) — Source: Artivion
- 2026-05-07 20:05 EST — [Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan](https://biopharmsignal.com/news/AORT/artivion-reports-first-quarter-2026-financial-results-and-announces-exercise-of-option-to-acquire-endospan) — Source: Artivion
- 2026-04-23 20:15 EST — [Artivion Announces Release Date and Teleconference Call Details for First Quarter 2026 Financial Results](https://biopharmsignal.com/news/AORT/artivion-announces-release-date-and-teleconference-call-details-for-first-quarter-2026-financial-results) — Source: Artivion
- 2026-04-07 11:00 EST — [Artivion Announces U.S. FDA Approval of the NEXUS® Aortic Arch System](https://biopharmsignal.com/news/AORT/artivion-announces-u-s-fda-approval-of-the-nexusr-aortic-arch-system) — Source: Artivion
- 2026-03-03 21:10 EST — [Artivion to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference](https://biopharmsignal.com/news/AORT/artivion-to-participate-in-the-oppenheimer-36th-annual-healthcare-medtech-and-services-conference) — Source: Artivion
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)